calanthe

(redirected from Cytheris)
Also found in: Thesaurus.

calanthe

(kæˈlænθɪ)
n
(Plants) any of various orchids of the genus Calanthe of the family Orchidaceae, found in tropical areas and having long-lasting yellow, white, or pink flowers
[C20: from New Latin, from Greek kalos beautiful + anthē bloom]
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.calanthe - any of various showy orchids of the genus Calanthe having white or yellow or rose-colored flowers and broad leaves folded lengthwisecalanthe - any of various showy orchids of the genus Calanthe having white or yellow or rose-colored flowers and broad leaves folded lengthwise
orchid, orchidaceous plant - any of numerous plants of the orchid family usually having flowers of unusual shapes and beautiful colors
genus Calanthe - large and widely distributed genus of terrestrial orchids
References in periodicals archive ?
2 February 2010 - French clinical-stage biopharmaceutical company Cytheris SA said today it has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for its patent application "Glycosylated IL-7, Preparation and Uses", US Patent Application No.
AT Salisbury Dick Hern's Cytheris, (J Mercer), a daughter of Crepello, is head and shoulders above the rest in the Upavon Stakes with Ian Balding's Gay Hat (P Waldron) getting the nod in second .
ClickPress, Fri Jul 19 2013] Global Market Direct's pharmaceuticals report, "Cytheris SA - Product Pipeline Review - 2013" provides data on the Cytheris SA's research and development focus.
By noting that the Muses have enlisted the aid of the goddess Venus, and referring to her by the epithet Cytherea, Sulpicia also calls to mind the actual name, Cytheris, of the woman Gallus celebrated by the pseudonym Lycoris.
PARIS -- Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim analysis of its ECLIPSE 2 Phase I/IIa study indicate that treatment with four weeks of the Company's investigative immune-modulator, recombinant human Interleukin-7 (CYT107), added to peginterferon and ribavirin (SOC) in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC, induces a broad immune response associated with HCV viral clearance in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC.
PARIS -- Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim analysis of its ECLIPSE 2 Hepatitis C Phase I/IIa multicenter study will be presented during a late breaker session at The Liver Meeting([R]), the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco, November 4-8, 2011.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, and the Cancer Immunotherapy Trials Network (CITN), a new initiative in immunotherapy funded by the National Cancer Institute with its Central Operations and Statistical Center (COSC) headquartered at Fred Hutchinson Cancer Research Center, Seattle, Washington, today announced the selection of recombinant human interleukin-7 (CYT107), the investigational multifunctional cytokine under development by Cytheris, as one of the first immunotherapeutic agents proposed for initial clinical trials at network institutions.
PARIS & LYON & GRENOBLE, France -- Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, the Centre Leon Berard (Lyon), the major cancer research and treatment center for the Rhyne-Alpes region of France, and ImmunID Technologies SAS (Grenoble), a diagnostic company specialized in innovative immunomonitoring tests and services, today announced initiation of a Phase IIa clinical trial that will evaluate multiple combinations of recombinant human interleukin-7 (CYT107), the investigational multifunctional cytokine under development by Cytheris, and a chemotherapeutic agent, XELODA([R]) (capecitabine, Roche/Genentech), in the treatment of metastatic breast cancer.
PARIS -- Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced results of a multi-center Phase IIa study designed to investigate the potential of Interleukin-7 (CYT107) therapy to reconstitute CD4 T-cells in chronically HIV-1 infected patients whose CD4 T-cell counts remained low despite treatment with anti-retroviral-therapies (HAART).
PARIS -- Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced publication of data showing that IL-7 is able to overcome many of the factors that thwart an effective immune response during chronic overwhelming viremia in diseases such as HIV infection and viral hepatitis.
PARIS -- Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced interim results from a Phase I clinical trial of its investigational drug candidate, recombinant human Interleukin-7 (CYT107), in the treatment of post-transplant patients with T-cell depleted (TCD) bone marrow or peripheral blood stem cell transplants.
PARIS -- Cytheris SA, a clinical-stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the publication of a case study report based on successful treatment of Progressive Multifocal Leukoencephalopathy (PML) with combination therapy consisting of two investigational agents, Cytheris' recombinant human interleukin-7 (CYT107) and CMX001, an investigational, oral broad-spectrum antiviral drug (Chimerix, Research Triangle Park, NC) in the Journal of Antimicrobial Chemotherapy.